What's in Danish Pain Research Center's pipeline?

Danish Pain Research Center has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Danish Pain Research Center's portfolio?

Top competitors by shared drug class: Seoul National University Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/danish-pain-research-center.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Danish Pain Research Center — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Danish Pain Research Center pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Oxycodone, fentanyl	Oxycodone, fentanyl	marketed	Opioid agonist combination	Mu-opioid receptor (OPRM1)	Pain Management

Therapeutic area mix

Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Seoul National University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Danish Pain Research Center:

Cite this brief

Drug Landscape (2026). Danish Pain Research Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/danish-pain-research-center. Accessed 2026-05-17.